Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@ExelixisInc Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::206746746.png) @ExelixisInc Exelixis

Exelixis posts on X about $exel, checkpoint the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::206746746/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::206746746/c:line/m:interactions.svg)

- X Week XXX +8,111%
- X Month XXXXX +530%
- X Months XXXXX -XX%
- X Year XXXXX -XX%

### Mentions: X [#](/creator/twitter::206746746/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::206746746/c:line/m:posts_active.svg)

- X Week X +200%
- X Month X +400%
- X Months XX -XX%
- X Year XX -XX%

### Followers: XXXXX [#](/creator/twitter::206746746/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::206746746/c:line/m:followers.svg)

- X Week XXXXX no change
- X Month XXXXX -XXXX%
- X Months XXXXX -XXXX%
- X Year XXXXX -XXXX%

### CreatorRank: undefined [#](/creator/twitter::206746746/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::206746746/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::206746746/influence)
---

**Social topic influence**
[$exel](/topic/$exel) #12, [checkpoint](/topic/checkpoint)

**Top assets mentioned**
[Exelixis Inc (EXEL)](/topic/$exel)
### Top Social Posts [#](/creator/twitter::206746746/posts)
---
Top posts by engagements in the last XX hours

"Just announced: Detailed results from the phase X pivotal trial of $EXEL novel oral kinase inhibitor in combination with an immune checkpoint inhibitor in metastatic #ColorectalCancer presented at #ESMO25 and published in @TheLancet. Learn more:"  
[X Link](https://x.com/ExelixisInc/status/1980164589519319538) [@ExelixisInc](/creator/x/ExelixisInc) 2025-10-20T06:50Z 5660 followers, XXX engagements


"See results from a subgroup analysis of the phase X pivotal trial evaluating $EXEL flagship therapy in patients with advanced #NeuroendocrineTumors (NET) at #ESMO25. Learn more:"  
[X Link](https://x.com/ExelixisInc/status/1979443962315264169) [@ExelixisInc](/creator/x/ExelixisInc) 2025-10-18T07:06Z 5657 followers, XXX engagements


"ATTN $EXEL Investors: Q3 earnings webcast coming soon. Details:"  
[X Link](https://x.com/ExelixisInc/status/1980729819727122868) [@ExelixisInc](/creator/x/ExelixisInc) 2025-10-21T20:16Z 5658 followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ExelixisInc Avatar @ExelixisInc Exelixis

Exelixis posts on X about $exel, checkpoint the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

  • X Week XXX +8,111%
  • X Month XXXXX +530%
  • X Months XXXXX -XX%
  • X Year XXXXX -XX%

Mentions: X #

Mentions Line Chart

  • X Week X +200%
  • X Month X +400%
  • X Months XX -XX%
  • X Year XX -XX%

Followers: XXXXX #

Followers Line Chart

  • X Week XXXXX no change
  • X Month XXXXX -XXXX%
  • X Months XXXXX -XXXX%
  • X Year XXXXX -XXXX%

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #


Social topic influence $exel #12, checkpoint

Top assets mentioned Exelixis Inc (EXEL)

Top Social Posts #


Top posts by engagements in the last XX hours

"Just announced: Detailed results from the phase X pivotal trial of $EXEL novel oral kinase inhibitor in combination with an immune checkpoint inhibitor in metastatic #ColorectalCancer presented at #ESMO25 and published in @TheLancet. Learn more:"
X Link @ExelixisInc 2025-10-20T06:50Z 5660 followers, XXX engagements

"See results from a subgroup analysis of the phase X pivotal trial evaluating $EXEL flagship therapy in patients with advanced #NeuroendocrineTumors (NET) at #ESMO25. Learn more:"
X Link @ExelixisInc 2025-10-18T07:06Z 5657 followers, XXX engagements

"ATTN $EXEL Investors: Q3 earnings webcast coming soon. Details:"
X Link @ExelixisInc 2025-10-21T20:16Z 5658 followers, XXX engagements

@ExelixisInc
/creator/twitter::ExelixisInc